Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
|Articles|December 11, 2017
FDA Accepts Lilly’s Application for Migraine Biologic
Author(s)BioPharm International Editors
FDA has accepted for review Eli Lilly and Company’s biologic drug candidate that is in development for treating migraine.
Advertisement
FDA has accepted a biologics license application (BLA) from Eli Lilly and Company to review galcanezumab, a monoclonal antibody (mAb) being developed to prevent migraine in adults, Lilly announced on Dec. 11, 2017. The biologic has been submitted for use as a once-monthly, self-administered injection in an auto-injector pen or prefilled syringe. Lilly announced the submission of the BLA in its third-quarter earnings call in October 2017.
Galcanezumab is specifically designed to bind to and inhibit the activity of calcitonin gene-related peptide (CGRP), which is believed to play a role in migraine and cluster headache. It is a part of Lilly’s pain portfolio and represents the first of three investigational, non-opioid treatments in development by the company. The portfolio also includes lasmiditan, for the acute treatment of migraine, and tanezumab, developed in partnership with Pfizer, for treating osteoarthritis, chronic low back pain, and cancer pain.
Source:
Advertisement
Related to this article
Phio's PH-762 posted a 70% response rate in skin cancer, supporting its FDA briefing package for a planned phase 2b trial.
Samsung Biologics signed a $262 million contract manufacturing agreement with an undisclosed European pharmaceutical company, extending production commitments through 2033 and lifting the CDMO's cumulative contract value past $21.9 billion.
Lundbeck's asedebart, which blocks ACTH signaling at its source, has won FDA orphan status for endogenous Cushingsyndrome.
Solstice Oncology launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody licensed from Harbour BioMed, into neoadjuvant Phase 2 testing for microsatellite-stable colon cancer.
Satralizumab cut MOGAD relapse risk 68% in a phase 3 trial, positioning it as the first potential treatment for this rare disease.
Ersodetug missed its phase 3 primary endpoint in congenital HI, but FDA is reviewing CGM data showing 50%+ hypoglycemia reductions.
Amgen and AstraZeneca announced that the Phase 3 DeLLphi-305 trial met its primary endpoint, with Imdelltra (tarlatamab) plus Imfinzi (durvalumab) significantly improving overall survival versus durvalumab alone as first-line maintenance therapy for extensive-stage small cell lung cancer — the first phase 3 study of a bispecific T-cell engager to show a survival benefit in this earlier-line setting.
Advertisement
Advertisement